急性缺血性脑卒中采取依达拉奉联合丁苯酞治疗的疗效和安全性探讨

贾蕾，王娟娟

（延安大学附属医院神经内科，陕西 延安，716000）

浏览次数：123次 下载次数：388次

摘要：

目的 探讨依达拉奉联合丁苯酞治疗急性缺血性脑卒中（CIS）的临床疗效和安全性。方法 将我院近3年收治的CIS患者120例随机分为对照组与联合组，各60例，两组均接受基础治疗，对照组采取依达拉奉+氯化钠静滴治疗，联合组在此基 础上加用丁苯酞，比较两组患者临床疗效和不良反应发生率。结果 治疗后，两组患者hs-CRP、TNF-α、IL-8、NIHSS 均显著降低，且联合组的各项指标明显低于对照组（P<0.05）。两组不良反应总发生率比较，无显著差异（P>0.05）。结论 依达拉奉联合丁苯酞治疗CIS，可有效改善神经功能损伤症状，疗效确切且不良反应少，值得临床应用。

关键词：急性缺血性脑卒中；依达拉奉；丁苯酞；安全性

中图分类号：R743.3文献标志码：A文章编号：2096-1413(2017)26-0014-02

Efficacy and safety of edaravone combined with butylphthalide in the treatment of cerebral ischemic stroke
JIA Lei, WANG Juan-juan
(Department of Neurology, the Affiliated Hospital of Yan``an University, Yan``an 716000, China)

ABSTRACT: Objective To investigate the clinical efficacy and safety of edaravone combined with butylphthalide in the treatment of cerebral ischemic stroke. Methods One hundred and twenty cases of CIS patients in our hospital for nearly 3 years were selected, which were randamly divided into control group and combined group, with 60 cases in each group. The two groups received basic treatment. The control group received edaravone and sodium chloride intravenous infusion, while the combined group added butylphthalide. The clinical efficacy and adverse reactions were compared between the two groups. Results After treatment, the hs-CRP, TNF-α, IL-8 and NIHSS scores in the two groups decreased, and the indexs in the combined group were lower than those in the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Edaravone combined with butylphthalide can effectively improve the symptoms of neurological dysfunction. The curative effect is good and the adverse reaction is small, which is worthy of clinical application.
KEYWORDS: cerebral ischemic stroke; edaravone; butylphthalide; safety

参考文献：
[1] 王陇德.中国脑卒中防治报告[M].北京:中国协和医科大学出版社,2015.
[2] 高星乐,陈力宇,孙乐球,等.依达拉奉联合丁苯酞治疗急性缺血性脑卒中的临床疗效及安全性评价[J].中国临床药理学杂志,2015，31(16):1569-1571.
[3] 中华医学会神经病学分会.中国急性缺血性脑卒中诊治指南2014 [J].中华神经科杂志,2015,48(4):246-257.
[4] 中华医学会神经病学分会脑血管病学组“卒中一级预防指”撰写组.中国卒中一级预防指南(2010)[J].中华神经科杂志,2011,44(4):282-288.
[5] 伊恋,李星达,王建秀,等.依达拉奉联合丁苯酞治疗急性缺血性脑卒中的临床观察[J].中国药房,2016,27(29):4130-4132.
[6] 梁海山,肖承年,奚振华,等.依达拉奉联合丁苯酞胶囊治疗急性缺血性脑卒中的临床研究及安全性分析[J].中国当代医药,2016,23(32):133-135.
[7] 刘喜艳,李会敏,张钦聪.丁苯酞与依达拉奉联用治疗急性进展性缺血性脑卒中的疗效[J].医学研究与教育,2015,32(5):14-17.
[8] 潘美靖,陈少川.依达拉奉联合丁苯酞对急性脑梗死患者的临床疗效[J].中国实用神经疾病杂志,2016,19(9):32-34.
[9] 申树民.丁苯酞联合依达拉奉改善急性缺血性脑血管病神经功能缺损的作用[J].当代医学,2016,22(1):133-134.
[10] 舒志刚,徐峻峰.丁苯酞治疗急性缺血性脑卒中临床疗效的系统评价[J].临床神经病学杂志,2016,29(1):1-7.